Results 121 to 130 of about 59,923 (283)

Carboxyhemoglobin blood level in indirect hyperbilirubinemia in term and late-preterm infants as a marker of hemolysis

Egyptian Pediatric Association Gazette
Background Neonatal hyperbilirubinemia remains one of the most common clinical conditions faced and one of the most common diagnoses requiring neonatal intensive care unit (NICU) admission, and this study aims to investigate whether carboxyhemoglobin ...
Dina Rabie, safaa shafik, Manal Mohsen, Ghada Salem   +3 more
doaj   +1 more source

Referee report. For: Assessment of adherence level for neonatal hyperbilirubinemia management by various physicians in Iraq: a multi-clinic study [version 1; peer review: 1 approved]

, 2020
Robert D. Christensen
openalex   +1 more source

Studies on the mechanism of Sn-protoporphyrin suppression of hyperbilirubinemia. Inhibition of heme oxidation and bilirubin production. [PDF]

, 1985
C S Simionatto, Karl E. Anderson, George S. Drummond, Attallah Kappas   +3 more
openalex   +1 more source

Isolated conjugated hyperbilirubinemia with rifampicin and cross-reaction with rifabutin: A drug-endogenous substance interaction case report

, 2023
S. Cohen, Charlotte Devant, Laure Delaval, Caroline Charlier, Étienne Canouï, Laurent Chouchana   +5 more
openalex   +1 more source

Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia‐Chromosome‐Positive Lymphoblastic Malignancies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama, Satoshi Ota, Yasuo Sakurai, Toma Suzuki, Naoki Miyashita, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Takeshi Kondo   +10 more
wiley   +1 more source

Hypertrophic pyloric stenosis: Early presentation with hyperbilirubinemia

, 2014
Rajeeva Mishra, Prabir Maji
openalex   +2 more sources

Tin-protoporphyrin suppression of hyperbilirubinemia in mutant mice with severe hemolytic anemia [PDF]

, 1983
S Sassa, GS Drummond, SE Bernstein, A Kappas   +3 more
openalex   +1 more source

Safety and Efficacy of Aumolertinib as First‐Line Treatment in EGFR‐Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single‐Arm, Prospective Phase II Study (ARISE Study)

MedComm, Volume 7, Issue 8, August 2026.
Aumolertinib treatment resulted in improved clinical activity in EGFR‐mutant ASC. ABSTRACT Lung adenosquamous carcinoma (ASC) is a rare histological subtype of non‐small cell lung cancer (NSCLC), and prospective data regarding the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in this patient population remain ...
Longfeng Zhang, Long Huang, Dingzhi Huang, Zhe Liu, Yongfeng Yu, Kang Miao, Qian Miao, Xiaobin Zheng, Yiquan Xu, Qian Chu, Gen Lin   +10 more
wiley   +1 more source

A STUDY OF HEARING EVALUATION FOR NEONATES WITH HYPERBILIRUBINEMIA USING OTOACOUSTIC EMISSION AND BRAIN STEM AUDITORY EVOKED RESPONSE

, 2014
Poornima Shankar, V C Manjunath
openalex   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, Volume 117, Issue 8, Page 2085-2097, August 2026.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source